The drug, Neupogen, is the first ever approved for the treatment of acute radiation injury and the approval came as a result of research performed by the University of Maryland School of Medicine (UM SOM) scientists, claims a study.
The investigators did their research in a non-human clinical model of high-dose radiation.
Radiation damages the bone marrow, and as a result decreases production of infection-fighting white blood cells. Neupogen counteracts these effects.
The drug, which is made by Amgen Inc., was first approved in 1991 to treat cancer patients receiving chemotherapy.
Although doctors may use it "off label" for other indications, the research and the resulting approval would speed up access to and use of the drug in the event of a nuclear incident, the study noted.
The research builds on 40 years of work that MacVittie and his team have conducted in the field of radiation research, during which they have helped to define the field.
- » News Central
- » Popular News
- » Latest Health News
- » News Category A-Z (500+)
- » Health News and Press Release
- » News Archive
- » News Photo Gallery
- » Lifestyle and Wellness
- » Health Watch
- » Health In Focus
- » Celebrating Life
- » Breaking Health News
- » News From Other Resources
- » India Special
- » News Video Gallery
- » Medindia Exclusive - Interviews and In depth Reports